이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ADC Therapeutics 관리

관리 기준 확인 3/4

ADC Therapeutics' CEO는 Ameet Mallik, May2022 에 임명되었습니다 의 임기는 2.08 년입니다. 총 연간 보상은 $ 3.78M, 19.1% 로 구성됩니다. 19.1% 급여 및 80.9% 보너스(회사 주식 및 옵션 포함). 는 $ 3.18M 가치에 해당하는 회사 주식의 1.21% 직접 소유합니다. 3.18M. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 3.6 년입니다.

주요 정보

Ameet Mallik

최고 경영자

US$3.8m

총 보상

CEO 급여 비율	19.1%
CEO 임기	2.4yrs
CEO 소유권	1.0%
경영진 평균 재임 기간	2.2yrs
이사회 평균 재임 기간	3.9yrs

최근 관리 업데이트

Recent updates

ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Jul 18

Limiting Concerns On ADC Therapeutics' Prospects

Jun 06

ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues

May 30

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

May 10

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

Mar 19

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

Mar 17

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

Jan 18

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

Dec 29

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

Dec 14

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

May 11

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Apr 18

ADC Therapeutics stock slips after pricing stock offering by seller

Feb 02

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

Jan 16

Jose Carmona joins ADC Therapeutics as CFO

Dec 19

ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M

Nov 08

ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval

Sep 16

ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11

Sep 09

ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M

Aug 09

CEO 보상 분석

Ameet Mallik 의 보수는 ADC Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$215m
Mar 31 2024	n/a	n/a	-US$227m
Dec 31 2023	US$4m	US$721k	-US$240m
Sep 30 2023	n/a	n/a	-US$182m
Jun 30 2023	n/a	n/a	-US$184m
Mar 31 2023	n/a	n/a	-US$200m
Dec 31 2022	US$11m	US$475k	-US$157m

보상 대 시장: Ameet 의 총 보상 ($USD 3.78M )은 US 시장( $USD 1.62M ).

보상과 수익: Ameet 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Ameet Mallik (51 yo)

2.4yrs

테뉴어

US$3,779,425

보상

Dr. Ameet Mallik M.B.A., M.S, is Director at ADC Therapeutics SA from June 30, 2022. He has been a Director of Atara Biotherapeutics, Inc. since August 2021. Dr. Mallik serves as Chief Executive Officer at...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ameet Mallik	CEO & Director	2.4yrs	US$3.78m	1.03% $ 3.1m
Jose Carmona	Chief Financial Officer	1.8yrs	US$1.26m	0.22% $ 657.8k
Mohamed Zaki	Chief Medical Officer	1.8yrs	US$4.40m	0.24% $ 728.0k
Lisa Kallebo	Corporate Controller & Chief Accounting Officer	no data	데이터 없음	데이터 없음
Michael Mulkerrin	Chief Technical Operations Officer	2.8yrs	데이터 없음	데이터 없음
Patrick van Berkel	Chief Scientific Officer	2.8yrs	데이터 없음	데이터 없음
Amanda Hamilton	Investor Relations Officer	no data	데이터 없음	데이터 없음
Peter Graham	Secretary & Chief Legal Officer	1.9yrs	데이터 없음	데이터 없음
Eugenia Litz	Vice President of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Kimberly Pope	Senior VP & Chief People Officer	4.2yrs	데이터 없음	데이터 없음
Kristen Harrington-Smith	Chief Commercial Officer	1.9yrs	데이터 없음	데이터 없음

2.2yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: ADCT 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ameet Mallik	CEO & Director	2.3yrs	US$3.78m	1.03% $ 3.1m
Michael Forer	Board Observer	1.3yrs	US$846.56k	데이터 없음
Peter Hug	Vice-Chairman & Lead Independent Director	5.3yrs	US$212.61k	0.15% $ 445.0k
Ron Squarer	Chairman of the Board	4.5yrs	US$526.73k	1.6% $ 4.8m
Jean-Pierre Bizzari	Independent Non-Executive Director	2.3yrs	US$197.81k	0.059% $ 177.5k
Tyrell Rivers	Independent Non-Executive Director	6.3yrs	데이터 없음	데이터 없음
Victor Sandor	Independent Non-Executive Director	4.5yrs	US$227.72k	0.074% $ 224.6k
Robert Azelby	Independent Director	1.3yrs	US$127.67k	0.024% $ 72.8k
Viviane Monges	Independent Non-Executive Director	3.3yrs	US$231.33k	0.098% $ 295.7k
Thomas Pfisterer	Non-Independent Director	8yrs	US$194.30k	0.18% $ 542.6k

3.9yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 이사회: ADCT 의 이사회는 경험(평균 재직 기간 3.6 년)으로 간주됩니다.

ADC Therapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

CEO & Director recently sold US$133k worth of stock

ADC Therapeutics SA, Annual General Meeting, Jun 13, 2024

High number of new directors

ADC Therapeutics SA Announces Evolution of Board of Directors

ADC Therapeutics SA, Annual General Meeting, Jun 14, 2023

ADC Therapeutics SA Announces Executive Changes

Recent updates

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ADC Therapeutics SA has filed a Follow-on Equity Offering in the amount of $100 million.

ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Limiting Concerns On ADC Therapeutics' Prospects

ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues

Consensus EPS estimates upgraded to US$1.84 loss, revenue downgraded

CEO & Director recently sold US$133k worth of stock

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $105 million.

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

ADC Therapeutics SA has filed a Follow-on Equity Offering.

ADC Therapeutics SA, Annual General Meeting, Jun 13, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

New minor risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

ADC Therapeutics: Navigating A Swirling Drain

New major risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Price target increased by 19% to US$10.50

Price target increased by 12% to US$8.80

New major risk - Share price stability

Consensus revenue estimates fall by 11%

ADC Therapeutics SA Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs At the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

ADC Therapeutics: Slowly Moving Toward Solvency

New major risk - Negative shareholders equity

Consensus revenue estimates decrease by 20%, EPS upgraded

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ADC Therapeutics SA to Report Q2, 2023 Results on Aug 08, 2023

China National Medical Products Administration Accepts Biologics License Application and Grants Priority Review for ZYNLONTA for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics SA Announces Voluntary Pause in the Enrollment of New Patients in the Phase 2 LOTIS-9 Clinical Trial Evaluating ZYNLONTA

Now 31% undervalued after recent price drop

Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?

High number of new directors

Price target decreased by 18% to US$9.33

ADC Therapeutics SA Announces Evolution of Board of Directors

ADC Therapeutics SA Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA(R) in Relapsed/Refractory DLBCL

ADC Therapeutics: Maybe A 2024 Story

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target increased by 9.4% to US$12.40

Consensus revenue estimates decrease by 29%, EPS upgraded

ADC Therapeutics SA Announces Updated Results from LOTIS-2 Trial to Be Presented at the European Hematology Association 2023 Hybrid Congress

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

ADC Therapeutics SA, Annual General Meeting, Jun 14, 2023

Price target increased by 8.5% to US$13.20

Price target increased by 7.4% to US$13.20

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Consensus revenue estimates fall by 16%

Price target decreased by 15% to US$11.14

Price target decreased by 8.5% to US$12.29

ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $60 million.

ADC Therapeutics stock slips after pricing stock offering by seller

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

ADC Therapeutics SA Announces Executive Changes

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

ADC Therapeutics Sa Appoints Jose Carmona as Chief Financial Officer

Jose Carmona joins ADC Therapeutics as CFO

Price target decreased to US$14.17

High number of new directors

Price target decreased to US$14.83

Price target increased to US$19.20